South Korea is to build a comprehensive database of genetic and biometric data from 10 million people, in a bid to boost its pharma and biotech industry.
Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.